GDNF and Parkinson disease: While successful in delivering GDNF across the BBB, a limitation of the intranasal mode of delivery presented here is that it is nonspecific in its targeting of brain regions, which means the mass dissemination of GDNF in the brain instead of focused on areas affected by early stage PD.